N-[(7-cyano-2-naphthyl)methyl][4-(4-methyl-1,4-diazepan-1-yl)phenyl]sulfamide | 220220-38-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-[(7-cyano-2-naphthyl)methyl][4-(4-methyl-1,4-diazepan-1-yl)phenyl]sulfamide
• 英文别名: N-(4-(4-methylhexahydro-1H-1,4-diazepin-1-yl)phenyl]-N-[(7-cyano-2-naphthyl)methyl]sulfamide；1-[4-[(7-cyanonaphthalen-2-yl)methyl-sulfamoylamino]phenyl]-4-methyl-1,4-diazepane
• CAS: 220220-38-2
• 化学式: C₂₄H₂₇N₅O₂S
• 分子量: 449.577
• InChiKey: VWOGHJPIAAQOKI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N-[(7-cyano-2-naphthyl)methyl][4-(4-methyl-1,4-diazepan-1-yl)phenyl]sulfamide 在 盐酸 、 ammonium acetate 作用下， 以 甲醇 、 氯仿 、 1,4-二氧六环 为溶剂， 反应 40.0h， 以30%的产率得到7-({(aminosulfonyl)[4-(4-methyl-1,4-diazepan-1-yl)phenyl]amino}methyl)naphthalene-2-carboximidamide 2.8 hydrochloride
  参考文献：
  名称：

  Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives

  摘要：

  Factor Xa (fXa) is a serine protease, which plays a pivotal role in the coagulation cascade. To improve the oral anticoagulant activity of fXa inhibitors containing a 1,4-diazepane moiety as the P4 part, a prodrug strategy was examined. Among the compounds evaluated in this study, amidoxime prodrugs bearing an ester moiety, Such as compounds 21 and 30, showed effective oral anticoagulant activity in mice. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.07.046
• 作为产物：
  描述：

  N-甲基高哌嗪 在 palladium on activated charcoal 吡啶 、 盐酸 、 氢气 、 三乙酰氧基硼氢化钠 、 potassium carbonate 、 溶剂黄146 作用下， 以 乙醇 、 二氯甲烷 、 氯仿 、 乙酸乙酯 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 47.0h， 生成 N-[(7-cyano-2-naphthyl)methyl][4-(4-methyl-1,4-diazepan-1-yl)phenyl]sulfamide
  参考文献：
  名称：

  Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives

  摘要：

  Factor Xa (fXa) is a serine protease, which plays a pivotal role in the coagulation cascade. To improve the oral anticoagulant activity of fXa inhibitors containing a 1,4-diazepane moiety as the P4 part, a prodrug strategy was examined. Among the compounds evaluated in this study, amidoxime prodrugs bearing an ester moiety, Such as compounds 21 and 30, showed effective oral anticoagulant activity in mice. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.07.046

文献信息

• Hexahydro-1,4-diazepine derivatives or salts thereof
  申请人：Yamanouchi Pharmaceutical Co.

  公开号：US06333320B1

  公开（公告）日：2001-12-25

  Hexahydro-1,4-diazepine derivatives represented by general formula (I); pharmaceutically acceptable salts thereof; and drugs containing the same as the active ingredient, such as activated blood coagulation factor X inhibitor, wherein A: phenylene, pyridylene, or the like; B: a 5- or 6-membered aryl or heteroaryl ring; X: —CO—, —CONH—, —CSNH—, —SO2—, —SO2NH—, or the like; Y: a bond or alkylene; R1: hydrogen, alkyl, —Y—(hetero) aryl, or the like; R2: hydrogen, alkoxy, —COOH, or the like; R3: amidino or a group capable of being converted into amidino; and R4, R5: each independently hydrogen or lower alkyl.

  通式(I)所表示的六氢-1,4-二氮杂环衍生物；其药学上可接受的盐；以及包含其作为活性成分的药物，例如活化血凝因子X抑制剂，其中A：苯撑基、吡啶撑基或类似物；B：5-或6-成员芳基或杂芳基环；X：—CO—、—CONH—、—CSNH—、—SO2—、—SO2NH—或类似物；Y：键或烷基；R1：氢、烷基、—Y—(杂)芳基或类似物；R2：氢、烷氧基、—COOH或类似物；R3：酰胺基或能够转化为酰胺基的基团；以及R4、R5：各自独立地为氢或低碳基。
• NOVEL HEXAHYDRO-1,4-DIAZEPINE DERIVATIVES OR SALTS THEREOF
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP1000936A1

  公开（公告）日：2000-05-17

  Hexahydro-1,4-diazepine derivatives represented by general formula (I); pharmaceutically acceptable salts thereof; and drugs containing the same as the active ingredient, such as activated blood coagulation factor X inhibitor, wherein A: phenylene, pyridylene, or the like; B: a 5- or 6-membered aryl or heteroaryl ring; X: -CO-, -CONH-, -CSNH-, -SO2-, -SO2NH-, or the like; Y: a bond or alkylene; R1: hydrogen, alkyl, -Y-(hetero)aryl, or the like; R2: hydrogen, alkoxy, -COOH, or the like; R3: amidino or a group capable of being converted into amidino; and R4, R5: each independently hydrogen or lower alkyl.

  由通式(I)代表的六氢-1,4-二氮杂卓衍生物；其药学上可接受的盐；以及以其为活性成分的药物，如活化凝血因子 X 抑制剂，其中 A：亚苯基、亚吡啶基或类似物；B：5 或 6 元芳基或杂芳基环；X：-CO-、-CONH-、-CSNH-、-SO2-、-SO2NH- 或类似物； Y：键或亚烷基； R1：氢、烷基、-Y-（杂）芳基或类似物； R2：氢、烷氧基、-COOH 或类似物； R3：脒基或可转化为脒基的基团；以及 R4、R5：各自独立的氢或低级烷基。
• US6333320B1
  申请人：——

  公开号：US6333320B1

  公开（公告）日：2001-12-25